Recently targeted kinases and their inhibitors-the path to clinical trials.

Recently targeted kinases and their inhibitors-the path to clinical trials.

Pokaži ostale verzije (1)

Protein kinases have emerged as one of the most important drug target families for the treatment of cancer. To date, 28 inhibitors with reported activity versus one or multiple kinases have been approved for clinical use. However, the majority of new clinical trials are focused on new subindications...

Bibliografski detalji
Glavni autori:	Knapp, S, Sundström, M
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2014

Slični predmeti

Recently targeted kinases and their inhibitors - the path to clinical trials
od: Knapp, S, i dr.
Izdano: (2014)

Insights for the development of specific kinase inhibitors by targeted structural genomics.
od: Fedorov, O, i dr.
Izdano: (2007)

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
od: Fedorov, O, i dr.
Izdano: (2007)

Targeting kinases for the treatment of inflammatory diseases.
od: Müller, S, i dr.
Izdano: (2010)

Kinase inhibitor selectivity profiling using differential scanning fluorimetry.
od: Fedorov, O, i dr.
Izdano: (2012)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
od: Ahn, Ryuhjin, i dr.
Izdano: (2021)

Development of bioreductive inhibitors of checkpoint kinase 1 to target hypoxic tumours
od: Körner, C
Izdano: (2015)

High-throughput structural characterisation of therapeutic protein targets.
od: Marsden, B, i dr.
Izdano: (2006)

High-throughput structural characterisation of therapeutic protein targets
od: Marsden, B, i dr.
Izdano: (2006)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
od: Akué-Gédu, R, i dr.
Izdano: (2009)

Discovery of BET bromodomain inhibitors and their role in target validation
od: Mueller, S, i dr.
Izdano: (2014)

The cysteinome of protein kinases as a target in drug development
od: Chaikuad, A, i dr.
Izdano: (2018)

A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
od: Taylor, M, i dr.
Izdano: (2017)

Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens
od: Beeharry, Neil, i dr.
Izdano: (2018)

Versatile selective kinase inhibitors: Chemistry and biology of indirubins
od: Gaboriaud-Kolar, N, i dr.
Izdano: (2012)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
od: Ciceri, P, i dr.
Izdano: (2014)

Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
od: Cowan-Jacob, S, i dr.
Izdano: (2014)

Functional characterization of the cyclin-dependent kinase inhibitor p21 by gene targeting in the mouse
od: Brugarolas, James (James Burfau), 1969-
Izdano: (2009)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
od: Bullock, A, i dr.
Izdano: (2009)

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.
od: Hellwig, S, i dr.
Izdano: (2012)

DFG-1 residue controls inhibitor binding mode and affinity, providing a basis for rational design of kinase inhibitor selectivity
od: Schröder, M, i dr.
Izdano: (2020)

Polynucleotide kinase as a potential target for enhancing cytotoxicity by ionizing radiation and topoisomerase I inhibitors.
od: Bernstein, N, i dr.
Izdano: (2008)

Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
od: Ekambaram, R, i dr.
Izdano: (2013)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
od: Bataille, C, i dr.
Izdano: (2017)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
od: Ciceri, P, i dr.
Izdano: (2014)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
od: Miduturu, C, i dr.
Izdano: (2011)

Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
od: Taipale, Mikko, i dr.
Izdano: (2014)

Identification and characterization of a small-molecule inhibitor of death-associated protein kinase 1.
od: Wilbek, T, i dr.
Izdano: (2015)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
od: Hamdi, Amir Imran Faisal, i dr.
Izdano: (2022)

Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors
od: Canning, P, i dr.
Izdano: (2015)

KOPI: kinase inhibitor proteome impact analysis
od: Li, Ginny Xiaohe, i dr.
Izdano: (2023)

Cinnamomum iners as Mitogen-Activated Protein Kinase Kinase (MKK1) inhibitor
od: Pang, Kam Lee, i dr.
Izdano: (2009)

Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach
od: Su, Ying, i dr.
Izdano: (2015)

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors
od: Suebsuwong, C, i dr.
Izdano: (2018)

Targeting tyrosine-kinases in ovarian cancer.
od: Morotti, M, i dr.
Izdano: (2013)

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype
od: Walter, A, i dr.
Izdano: (2018)

Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors.
od: Feng, L, i dr.
Izdano: (2011)

A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination
od: Rudolf, A, i dr.
Izdano: (2014)

Targeting the water network in cyclin G-associated kinase (GAK) with 4-anilino-quin(az)oline inhibitors
od: Asquith, CRM, i dr.
Izdano: (2020)

Recent progress in histone demethylase inhibitors
od: McAllister, T, i dr.
Izdano: (2016)